Medtronic, a Dublin-based multinational medical technology company, today announced the acquisition of Bellco, a leading Italian company in hemodialysis solutions, based in the technological hub of Mirandola, in Emilia. In this way, the Bellco portfolio will consolidate Medtronic's offer of the new Renal Care Solutions Division.
Bellco has created, through its own research, a therapies and systems for the treatment of renal insufficiency, multi-organ dysfunction, sepsis and has a complete line of dialyzers and equipment for acute and chronic dialysis in adult, pediatric and neonatal patients with end-stage renal disease. The company has been active for 40 years and is present in 50 countries around the world.
"The acquisition of an important company such as Bellco, one of the symbols of Italian excellence in the Mirandola technological hub, demonstrates how much Medtronic continues to believe in our country - he declares Luciano Frattini, President and CEO of Medtronic Italy – Medtronic, following the recent acquisition of Covidien, is already present in the Mirandola area with its own production unit, and this important step confirms the investment strategy in the Italian medical excellence already started a few years ago, with the acquisition of relevant Made in Italy brands such as Invatec and NGC. Our goal is to enhance these national realities, further strengthening them thanks to the strength of over 1,5 billion investments in research and development, and the Group's presence in over 155 countries. Today, by aiming at Bellco, we confirm that we want to believe in the resources and know-how of our country, certain that it knows how to continue investing in innovation as a way to guarantee the sustainability of our Healthcare System. The benefit of a product with high added value, in fact, derives from a greater efficacy of the treatment for patients, and from an optimization of the overall expense."
“Patients with end-stage renal disease need dialysis for their entire lives, or until there is the possibility of a kidney transplant. Medtronic's Renal Care Solutions Division is able to offer the best and most accessible solutions for these patients who are constantly increasing” – he declares Fri Manda, President of Medtronic's Renal Care Solutions (RCS) Group. “Integrating Bellco's portfolio of solutions will allow Medtronic to complete its treatment offerings for dialysis patients worldwide.”
Medtronic has acquired Italy's Bellco from Charme Capital Partners, head of pan-European Charme funds. The terms of the acquisition were not disclosed. “I think Medtronic is a great opportunity for the Bellco team and for ESRD patients around the world. In four years, we have created the ideal conditions to attract the interest of a global leader able to support Bellco in a long-term growth strategy” – he declared Matthew of Montezemolo, Founder and Managing Partner of the Charme Funds.
